Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Receives Average Rating of “Buy” from Analysts

September 28, 2025

[ad_1]

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA – Get Free Report) have earned a consensus rating of “Buy” from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. Nine equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $32.3750.

CNTA has been the subject of a number of recent research reports. Wall Street Zen cut shares of Centessa Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 16th. Truist Financial initiated coverage on shares of Centessa Pharmaceuticals in a research note on Monday, July 21st. They set a “buy” rating and a $30.00 price target for the company. Lifesci Capital upgraded shares of Centessa Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, September 3rd. Oppenheimer started coverage on shares of Centessa Pharmaceuticals in a research note on Friday, August 29th. They set an “outperform” rating and a $40.00 price target for the company. Finally, Wells Fargo & Company started coverage on shares of Centessa Pharmaceuticals in a research note on Wednesday, September 3rd. They issued an “overweight” rating and a $31.00 target price for the company.

Read Our Latest Stock Analysis on CNTA

Insider Activity

Want More Great Investing Ideas?

In other news, insider Gregory M. Weinhoff sold 10,000 shares of the firm’s stock in a transaction on Friday, July 25th. The shares were sold at an average price of $15.56, for a total value of $155,600.00. Following the completion of the sale, the insider owned 122,279 shares in the company, valued at approximately $1,902,661.24. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CTO Tia L. Bush sold 35,000 shares of the firm’s stock in a transaction on Wednesday, September 24th. The stock was sold at an average price of $24.00, for a total transaction of $840,000.00. Following the completion of the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at $2,916,072. This trade represents a 22.36% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 205,286 shares of company stock worth $3,993,345 over the last quarter. Insiders own 7.09% of the company’s stock.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in CNTA. Caitong International Asset Management Co. Ltd lifted its stake in shares of Centessa Pharmaceuticals by 15,209.5% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,215 shares of the company’s stock worth $46,000 after acquiring an additional 3,194 shares during the period. Osterweis Capital Management Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at about $47,000. Bank of New York Mellon Corp acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at about $147,000. Fox Run Management L.L.C. acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at about $160,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Centessa Pharmaceuticals in the first quarter valued at about $214,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 1.1%

Shares of NASDAQ:CNTA opened at $23.26 on Monday. The stock has a market cap of $3.11 billion, a P/E ratio of -12.99 and a beta of 1.47. The firm has a fifty day moving average price of $18.34 and a 200 day moving average price of $15.08. The company has a debt-to-equity ratio of 0.32, a current ratio of 10.11 and a quick ratio of 10.12. Centessa Pharmaceuticals has a 1-year low of $9.60 and a 1-year high of $24.13.

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.03). Sell-side analysts predict that Centessa Pharmaceuticals will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Company Profile

(Get Free Report)

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.